Kylin Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Kylin Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,800	Closed	-$256K	–	10
2015 Q4	$256K	Buy	+1,800	New	+$208K	0.03%	8
2015 Q3	–	Sell	-188,226	Closed	-$21.7M	–	8
2015 Q2	$21.7M	Buy	+188,226	New	+$19.8M	2.36%	6

Other funds holding CBPO

Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ICP

Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kylin Management's CBPO Position: Q1 2016 in Review

Kylin Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2016, closing a stake of 1,800 shares — an estimated $256K sold.

Kylin Management first reported a position in CBPO in Q2 2015 and held it in 2 quarters. The position peaked at $21.7M in Q2 2015. 131 funds tracked by Wall St. Rank hold CBPO as of Q1 2016.

Kylin Management reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2016 after selling out during the quarter.
Kylin Management sold 1,800 China Biologic Products Holdings, Inc. shares in Q1 2016, an estimated $256K.
Kylin Management first reported a position in China Biologic Products Holdings, Inc. in Q2 2015 and held it in 2 quarters.
Kylin Management's China Biologic Products Holdings, Inc. position peaked at $21.7M in Q2 2015.
131 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2016.

Based on Kylin Management's 13F filing for Q1 2016, filed 13 May 2016.